Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura

OBJECTIVE: To investigate the efficacy and safety of rituximab (RTX) as first-line treatment of acquired thrombotic thrombocytopenic purpura (aTTP). METHODS: Twenty-five patients with acute aTTP and/or severe a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Int Med Res
Main Authors: Chen, Haifei, Fu, Ailin, Wang, Jing, Wu, Tianqin, Li, Zhengyang, Tang, Jieqing, Shen, Hongshi, Zhu, Jingjing, Li, Jie, Zhu, Qian, Qing, Longmei
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2017
Assuntos:
Clinical Note
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5536423/
https://ncbi.nlm.nih.gov/pubmed/28639502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0300060517695646
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados